{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:21:09Z","timestamp":1759335669204,"version":"3.32.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,23]]},"DOI":"10.7759\/cureus.76265","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T18:04:44Z","timestamp":1734977084000},"source":"Crossref","is-referenced-by-count":1,"title":["Rasburicase Plus Methotrexate Combination Therapy in a Case of Tophaceous, Difficult-to-Treat Gout"],"prefix":"10.7759","author":[{"given":"Maria Fernanda","family":"Pino-Zambrano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricio","family":"Cardoso Pe\u00f1afiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Calvo-Aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette P","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, et al.. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017, 76:29-42. 10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1297-319X(15)30003-8","article-title":"Canakinumab for the patient with difficult-to-treat gouty arthritis: review of the clinical evidence","volume":"82","author":"Bardin T","year":"2015","unstructured":"Bardin T. Canakinumab for the patient with difficult-to-treat gouty arthritis: review of the clinical evidence. Joint Bone Spine. 2015, 82:9-16. 10.1016\/S1297-319X(15)30003-8","journal-title":"Joint Bone Spine"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01006-3","article-title":"Mechanisms and rationale for uricase use in patients with gout","volume":"19","author":"Schlesinger N","year":"2023","unstructured":"Schlesinger N, P\u00e9rez-Ruiz F, Liot\u00e9 F. Mechanisms and rationale for uricase use in patients with gout. Nat Rev Rheumatol. 2023, 19:640-9. 10.1038\/s41584-023-01006-3","journal-title":"Nat Rev Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.09.045","article-title":"Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome","volume":"116","author":"Davidson MB","year":"2004","unstructured":"Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004, 116:546-54. 10.1016\/j.amjmed.2003.09.045","journal-title":"Am J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh629","article-title":"Urate oxidase (rasburicase) for treatment of severe tophaceous gout","volume":"20","author":"Vogt B","year":"2005","unstructured":"Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant. 2005, 20:431-3. 10.1093\/ndt\/gfh629","journal-title":"Nephrol Dial Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0214","article-title":"Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol","volume":"2","author":"Richette P","year":"2006","unstructured":"Richette P, Bardin T. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol. 2006, 2:338-42; quiz 343. 10.1038\/ncprheum0214","journal-title":"Nat Clin Pract Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.05.009","article-title":"Resolution of massive tophaceous gout with three urate-lowering drugs","volume":"126","author":"Mej\u00eda-Chew C","year":"2013","unstructured":"Mej\u00eda-Chew C, Torres RJ, de Miguel E, Puig JG. Resolution of massive tophaceous gout with three urate-lowering drugs. Am J Med. 2013, 126:e9-10. 10.1016\/j.amjmed.2013.05.009","journal-title":"Am J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-0043-y","article-title":"Rasburicase treatment in severe tophaceous gout: a novel therapeutic option","volume":"25","author":"Moolenburgh JD","year":"2006","unstructured":"Moolenburgh JD, Reinders MK, Jansen TL. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol. 2006, 25:749-52. 10.1007\/s10067-005-0043-y","journal-title":"Clin Rheumatol"},{"key":"ref9","article-title":"[Rasburicase for tophaceus gout treatment]","volume":"34","author":"Ribeiro A","year":"2009","unstructured":"Ribeiro A, Bogas M, Costa J, Costa L, Araujo D. [Rasburicase for tophaceus gout treatment]. Acta Reumatol Port. 2009, 34:551-4.","journal-title":"Acta Reumatol Port"},{"key":"ref10","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study","volume":"34","author":"Richette P","year":"2007","unstructured":"Richette P, Briere C, Hoenen-Clavert V, Loeuille D, Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol. 2007, 34:2093-8.","journal-title":"J Rheumatol"},{"key":"ref11","article-title":"Urate oxidase (rasburicase) for treatment of severe acute gout: a case report","volume":"27","author":"Wipfler-Freibmuth E","year":"2009","unstructured":"Wipfler-Freibmuth E, Dejaco C, Duftner C, Gaugg M, Kriessmayr-Lungkofler M, Schirmer M. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report. Clin Exp Rheumatol. 2009, 27:658-60.","journal-title":"Clin Exp Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky PE","year":"2014","unstructured":"Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014, 16:R60. 10.1186\/ar4497","journal-title":"Arthritis Res Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201795","article-title":"Long-term safety of pegloticase in chronic gout refractory to conventional treatment","volume":"72","author":"Becker MA","year":"2013","unstructured":"Becker MA, Baraf HS, Yood RA, et al.. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013, 72:1469-74. 10.1136\/annrheumdis-2012-201795","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02865-z","article-title":"A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study","volume":"24","author":"Botson JK","year":"2022","unstructured":"Botson JK, Tesser JR, Bennett R, et al.. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study. Arthritis Res Ther. 2022, 24:208. 10.1186\/s13075-022-02865-z","journal-title":"Arthritis Res Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037424","article-title":"Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: a retrospective case series","volume":"103","author":"Albert J","year":"2024","unstructured":"Albert J, Broadwell A, Padnick-Silver L, Marder B, LaMoreaux B. Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: a retrospective case series. Medicine (Baltimore). 2024, 103:e37424. 10.1097\/MD.0000000000037424","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/318382-rasburicase-plus-methotrexate-combination-therapy-in-a-case-of-tophaceous-difficult-to-treat-gout","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T18:04:45Z","timestamp":1734977085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/318382-rasburicase-plus-methotrexate-combination-therapy-in-a-case-of-tophaceous-difficult-to-treat-gout"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.76265","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,23]]}}}